K Pharma,Inc.
TTSE:4896676.00
JPY
-46.00
(-6.37%)
K Pharma,Inc.
TSE:4896
(Tokyo Stock Exchange)
Recent
price
676.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.- Similar Companies
- Business
- K Pharma, Inc. engages in the research, development, manufacture, and sale of regenerative medicines and pharmaceutical products in Japan. Its core products include regenerative medicine products developed using disease-specific induced pluripotent stem (iPS) cell technology targeting spinal cord injuries and cerebral infarctions, and iPS-based drug discovery platforms particularly for nerve regeneration and diseases such as amyotrophic lateral sclerosis (ALS). Founded in 2016 as a spin-off from Keio University School of Medicine, K Pharma leverages academic research to advance innovative medical treatments and operates primarily in Japan with its headquarters in Minato, Tokyo. In terms of recent major changes, K Pharma has formed a strategic business alliance with Alfresa Holdings and its subsidiary Alfresa to collaborate on the supply chain for regenerative medicine products derived from iPS cells, including the clinical trial product and planned commercial drug KP8011 for subacute spinal cord injury. The company has initiated domestic clinical trials for ALS treatment within its iPS drug development pipeline, reflecting a key milestone in its pharmaceutical R&D efforts. Financially, 2025 has seen revisions in operating and net income forecasts with ongoing investment in research, reflecting an expansion and deepening of its regenerative medicine and drug discovery activities. K Pharma targets the healthcare and biotechnology industry, offering advanced regenerative medicines and pharmaceutical solutions primarily to clinical and research institutions. The company continues to focus on therapies that address nerve damage and neurological conditions through innovative iPS cell technology, contributing to next-generation medical treatments. It remains a single-segment operation with a strong academic and scientific foundation, positioning itself as a pioneer in the regenerative medicine space in Japan and potentially broader markets through collaborative development and clinical validation programs.